MedPath

Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication

Phase 3
Completed
Conditions
Peripheral Arterial Occlusive Disease
Interventions
Drug: Placebo, Oral intake single dose
Registration Number
NCT02832570
Lead Sponsor
University Hospital, Angers
Brief Summary

Efffect of a single dose oral intake of sildenafil Or placebo on the walking capacity on treadmill of PAD patients with claudication

Detailed Description

Sildenafil 100mg or Placebo Oral intake 2 hours before the treadmill test Safety and security control throughout the period of drug efficacy (approx 4 hours) Evaluation of maximal walking distance for a constant load treadmill test (3.2 kml/h 10% slope)

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • Patient with peripheral arterial desease stade II
  • Patient with vascular claudication for at least 3 months
  • Patient able to perform a treadmill walking test with time to walk < 5min
Exclusion Criteria
  • Patient suffering from ischemia
  • Previous angina or myocardial
  • Patient treated with nitrates drugs
  • Patient with severe renal insufficiency
  • Patient with severe hepatic insufficiency
  • Patient with hypotension

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo, Oral intake single doseSingle placebo intake approximately 2 hours before the treadmill test.
SildenafilSildenafil 100mg single oral doseSingle sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
Primary Outcome Measures
NameTimeMethod
Walking duration on treadmill2 hours after treatment intake

Treadmill test with consttant load procedure 3.2 km/h H 10% slope up to 15 minutes followed by incremental load according tpo the Bruce protocole thereafter.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath